Patients with SSc who have positive anti-topoisomerase (Scl-70) antibodies, may be at greater risk of developing ILD and disease progression, compared with limited cutaneous systemic sclerosis or positive anti-centromere antibodies.
The majority of patients with SSc-ILD have positive antinuclear antibodies, which may be accompanied by anti-topoisomerase I (anti-Scl-70), anti-Th/To, anti-U3 ribonucleoprotein (RNP), anti-U11/U12 RNP or, rarely, anti-centromere antibodies.
Other risk factors for progression in Ssc-ILD include presence of diffuse disease, extent of parenchymal disease on HRCT of more than 20%, FVC of less than 70%, and the detection of anti-topoisomerase antibody.
Learn more about CTD-ILD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis - Medscape - Jan 28, 2022.